Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Previous studies have suggested an increased risk of bladder cancer with pioglitazone exposure. We aimed to investigate the association between pioglitazone exposure and bladder cancer in France. METHODS: This cohort study involved use of data from the French national health insurance information system (Système National d'Information Inter-régimes de l'Assurance Maladie; SNIIRAM) linked with the French hospital discharge database (Programme de Médicalisation des Systèmes d'Information; PMSI). The cohort included patients aged 40 to 79 years who filled a prescription for a glucose-lowering drug in 2006. The cohort was followed for up to 42 months. Pioglitazone exposure was modelled as a time-dependent variable and defined by having filled at least two prescriptions over a 6-month period. Incident cases of bladder cancer were identified by a discharge diagnosis of bladder cancer combined with specific aggressive treatment. Statistical analyses involved a multivariate Cox model adjusted for age, sex and exposure to other glucose-lowering drugs. RESULTS: The cohort included 1,491,060 diabetic patients, 155,535 of whom were exposed to pioglitazone. We found 175 cases of bladder cancer among exposed patients and 1,841 among non-exposed patients. Incidence rates were 49.4 and 42.8 per 100,000 person-years, respectively. Pioglitazone exposure was significantly associated with bladder cancer incidence (adjusted HR 1.22 [95% CI 1.05, 1.43]). We observed a dose-effect relationship, with a significantly increased risk for high cumulative doses (≥ 28,000 mg, adjusted HR 1.75 [95% CI 1.22, 2.50]) and long duration of exposure (≥ 24 months, adjusted HR 1.36 [1.04, 1.79]). CONCLUSIONS/INTERPRETATION: In this cohort of diabetic patients from France, pioglitazone exposure was significantly associated with increased risk of bladder cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Observational research conducted in 2011 and 2012 suggested that pioglitazone may increase the risk of bladder cancer.46,47”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“After a blinded review with external experts, bladder cancer was diagnosed during the second year of exposure in six cases in the pioglitazone group vs three in the placebo group [4, 5].”
BackgroundMetformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“This observation has been previously reported [14–17].”
Association Between Smoking and Risk of Bladder Cancer Among Men and Women
Freedman, N. D. (2011) · JAMA · doi:10.1001/jama.2011.1142 · Cited by 1,141 · cited 1×
“First of all, it lacks data on tobacco use, known to be the third main risk factor for bladder cancer after age and male sex [19, 20].”
BackgroundThe influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
French national health insurance information system and the permanent beneficiaries sample
Tuppin, P., de Roquefeuil, L., Weill, A., Ricordeau, P., & Merlière, Y. (2010) · Revue d'Épidémiologie et de Santé Publique · doi:10.1016/j.respe.2010.04.005 · Cited by 399 · cited 1×
“The national health insurance information system (Système National d'Information Inter-régimes de l'Assurance Maladie; SNIIRAM) contains individualised, anonymous and exhaustive data on all reimbursements for patient health expenditure [10], including medicinal products as well as outpatient medical and nursing care,…”
BackgroundSelf-citationDiabetes mellitus and risk of bladder cancer: a meta-analysis
Larsson, S. C., Orsini, N., Brismar, K., & Wolk, A. (2006) · Diabetologia · doi:10.1007/s00125-006-0468-0 · Cited by 304 · cited 1×
“42]) when comparing type 2 diabetic individuals with non-diabetic individuals [22].”
BackgroundDormandy, J., Bhattacharya, M., & van Troostenburg de Bruyn, A.-R. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 227
Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
Ferrara, A., Lewis, J. D., Quesenberry, C. P., Peng, T., Strom, B. L., Van Den Eeden, S. K., Ehrlich, S. F., & Habel, L. A. (2011) · Diabetes Care · doi:10.2337/dc10-1067 · Cited by 181 · cited 1×
“Another analysis of a similar cohort found no association between pioglitazone exposure and cancer in several other sites [7].”
Result
Research works printed but not linked: 1
- French medicines agency (AFSSAPS) (2011) Use of medications containing pioglitazone (Actos®, Competact®) Suspended. Available from www.afssaps.fr/content/download/34175/447382/version/1/file/Press-release-Suspension-Pioglitazone.pdf , accessed 12 August 2011.
Cited by
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Tuppin, P., Rudant, J., Constantinou, P., Gastaldi-Ménager, C., Rachas, A., de Roquefeuil, L., Maura, G., Caillol, H., Tajahmady, A., Coste, J., et al. (2017) · Revue d'Épidémiologie et de Santé Publique · doi:10.1016/j.respe.2017.05.004 · Cited by 891
Self-citationObesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
“These studies included data from an adverse events reporting database (155), a nested case control study (10), a retrospective cohort study (144), and two meta-analyses of studies (54, 217).”
BackgroundPPARγ and the global map of adipogenesis and beyond
Lefterova, M. I., Haakonsson, A. K., Lazar, M. A., & Mandrup, S. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.04.001 · Cited by 623
Metadata
- Authors
- Neumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H.
- Affiliations
- l'Assurance Maladie (FR)
- Corresponding author
- Weill, A.
- Venue
- Diabetologia
- Published
- 2012-03-31
- Volume
- 55
- Issue
- 7
- Pages
- 1953-1962
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC3369136
- OpenAlex
- W2145777529
- Cited by
- 284
- References
- 16
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 9 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 8 · 2019: 17 · 2018: 21 · 2017: 24 · 2016: 30 · 2015: 31 · 2014: 40 · 2013: 49 · 2012: 22
- FWCI
- 18.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Diabetologia (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pioglitazone, bladder cancer, diabetes mellitus, drug-induced cancer risk, thiazolidinediones, antidiabetic drugs, dose-response relationship, drug exposure duration, cancer incidence
- MeSH terms
- Pioglitazone, Adult, Aged, Urinary Bladder Neoplasms, Diabetes Mellitus, Type 2, Drug Administration Schedule, Female, Follow-Up Studies, France, Humans, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Cohort Studies, Incidence, Multivariate Analysis, Proportional Hazards Models, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. https://app.cochat.ai/papers/10.1007/s00125-012-2538-9
- The paper
- Neumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H. (2012). Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. https://doi.org/10.1007/s00125-012-2538-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
